Literature DB >> 15062559

Gadd45gamma is androgen-responsive and growth-inhibitory in prostate cancer cells.

Feng Jiang1, Zhou Wang.   

Abstract

In our previous microarray analysis searching for genes differentially regulated by androgens in the rat ventral prostate, we identified GADD45gamma (growth arrest and DNA damage inducible, gamma) as one of the genes up-regulated by androgens. GADD45gamma was initially identified to be a gene involved in negative growth control and its overexpression induced cycle arrest and apoptosis in vitro. In this study, we showed that GADD45gamma was transiently up-regulated by androgens in the androgen-responsive human prostate cancer cell line LNCaP. The GADD45gamma up-regulation was blocked by an androgen receptor (AR) antagonist, bicalutamide, suggesting the involvement of the androgen receptor. However, this up-regulation was inhibited by cycloheximide, indicating that GADD45gamma induction by androgens requires new protein synthesis. Overexpression of GADD45gamma inhibited cell growth of LNCaP and PC3 cells and resulted in dramatic morphological changes in both cell lines, arguing that GADD45gamma is likely to participate in the differentiation program induced by androgens in the prostate. The above observations provide evidence that GADD45gamma is an androgen-responsive gene with growth-inhibitory activity in human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15062559     DOI: 10.1016/j.mce.2003.10.050

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Gadd45 proteins: relevance to aging, longevity and age-related pathologies.

Authors:  Alexey A Moskalev; Zeljka Smit-McBride; Mikhail V Shaposhnikov; Ekaterina N Plyusnina; Alex Zhavoronkov; Arie Budovsky; Robi Tacutu; Vadim E Fraifeld
Journal:  Ageing Res Rev       Date:  2011-10-05       Impact factor: 10.895

2.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

3.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

4.  Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes.

Authors:  Weiqi Tan; Michelle A T Hildebrandt; Xia Pu; Maosheng Huang; Jie Lin; Surena F Matin; Pheroze Tamboli; Christopher G Wood; Xifeng Wu
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

5.  GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.

Authors:  Omar Flores; Kerry L Burnstein
Journal:  Endocrinology       Date:  2010-08-25       Impact factor: 4.736

Review 6.  Gadd45 proteins as critical signal transducers linking NF-kappaB to MAPK cascades.

Authors:  Z Yang; L Song; C Huang
Journal:  Curr Cancer Drug Targets       Date:  2009-12       Impact factor: 3.428

7.  1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.

Authors:  Michele N Washington; Jung-Sun Kim; Nancy L Weigel
Journal:  Prostate       Date:  2011-01-01       Impact factor: 4.104

8.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

Authors:  Anna Scuto; Mark Kirschbaum; Claudia Kowolik; Leo Kretzner; Agnes Juhasz; Peter Atadja; Vinod Pullarkat; Ravi Bhatia; Stephen Forman; Yun Yen; Richard Jove
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

9.  Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.

Authors:  Natalia D Tararova; Natalya Narizhneva; Vadim Krivokrisenko; Andrei V Gudkov; Katerina V Gurova
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.